PortfoliosLab logo
KRYS vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between KRYS and LLY is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

KRYS vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

800.00%1,000.00%1,200.00%1,400.00%1,600.00%1,800.00%2,000.00%AugustSeptemberOctoberNovemberDecember2025
1,337.22%
997.42%
KRYS
LLY

Key characteristics

Sharpe Ratio

KRYS:

0.32

LLY:

0.95

Sortino Ratio

KRYS:

1.11

LLY:

1.50

Omega Ratio

KRYS:

1.13

LLY:

1.19

Calmar Ratio

KRYS:

0.65

LLY:

1.19

Martin Ratio

KRYS:

1.48

LLY:

3.12

Ulcer Index

KRYS:

12.53%

LLY:

9.20%

Daily Std Dev

KRYS:

57.99%

LLY:

30.16%

Max Drawdown

KRYS:

-53.42%

LLY:

-68.27%

Current Drawdown

KRYS:

-28.43%

LLY:

-16.54%

Fundamentals

Market Cap

KRYS:

$4.51B

LLY:

$707.96B

EPS

KRYS:

$1.79

LLY:

$9.28

PE Ratio

KRYS:

87.53

LLY:

84.83

Total Revenue (TTM)

KRYS:

$199.38M

LLY:

$31.51B

Gross Profit (TTM)

KRYS:

$182.28M

LLY:

$25.63B

EBITDA (TTM)

KRYS:

$51.83M

LLY:

$9.48B

Returns By Period

In the year-to-date period, KRYS achieves a -2.39% return, which is significantly lower than LLY's 3.61% return.


KRYS

YTD

-2.39%

1M

-11.81%

6M

-24.72%

1Y

19.13%

5Y*

26.58%

10Y*

N/A

LLY

YTD

3.61%

1M

2.24%

6M

-15.40%

1Y

25.23%

5Y*

43.93%

10Y*

30.17%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Krystal Biotech, Inc.

Eli Lilly and Company

Risk-Adjusted Performance

KRYS vs. LLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS
The Risk-Adjusted Performance Rank of KRYS is 6666
Overall Rank
The Sharpe Ratio Rank of KRYS is 6262
Sharpe Ratio Rank
The Sortino Ratio Rank of KRYS is 6565
Sortino Ratio Rank
The Omega Ratio Rank of KRYS is 6262
Omega Ratio Rank
The Calmar Ratio Rank of KRYS is 7474
Calmar Ratio Rank
The Martin Ratio Rank of KRYS is 6666
Martin Ratio Rank

LLY
The Risk-Adjusted Performance Rank of LLY is 7777
Overall Rank
The Sharpe Ratio Rank of LLY is 7979
Sharpe Ratio Rank
The Sortino Ratio Rank of LLY is 7474
Sortino Ratio Rank
The Omega Ratio Rank of LLY is 7373
Omega Ratio Rank
The Calmar Ratio Rank of LLY is 8484
Calmar Ratio Rank
The Martin Ratio Rank of LLY is 7676
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

KRYS vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for KRYS, currently valued at 0.32, compared to the broader market-4.00-2.000.002.000.320.95
The chart of Sortino ratio for KRYS, currently valued at 1.11, compared to the broader market-4.00-2.000.002.004.001.111.50
The chart of Omega ratio for KRYS, currently valued at 1.13, compared to the broader market0.501.001.502.001.131.19
The chart of Calmar ratio for KRYS, currently valued at 0.65, compared to the broader market0.002.004.006.000.651.19
The chart of Martin ratio for KRYS, currently valued at 1.48, compared to the broader market0.0010.0020.001.483.12
KRYS
LLY

The current KRYS Sharpe Ratio is 0.32, which is lower than the LLY Sharpe Ratio of 0.95. The chart below compares the historical Sharpe Ratios of KRYS and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00AugustSeptemberOctoberNovemberDecember2025
0.32
0.95
KRYS
LLY

Dividends

KRYS vs. LLY - Dividend Comparison

KRYS has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.65%.


TTM20242023202220212020201920182017201620152014
KRYS
Krystal Biotech, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.65%0.67%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%

Drawdowns

KRYS vs. LLY - Drawdown Comparison

The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for KRYS and LLY. For additional features, visit the drawdowns tool.


-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-28.43%
-16.54%
KRYS
LLY

Volatility

KRYS vs. LLY - Volatility Comparison

Krystal Biotech, Inc. (KRYS) has a higher volatility of 14.03% compared to Eli Lilly and Company (LLY) at 6.57%. This indicates that KRYS's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%16.00%AugustSeptemberOctoberNovemberDecember2025
14.03%
6.57%
KRYS
LLY

Financials

KRYS vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Krystal Biotech, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B2020AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJuly
83.84M
11.44B
(KRYS) Total Revenue
(LLY) Total Revenue
Values in USD except per share items

User Portfolios with KRYS or LLY


Draft 2
16%
YTD
LLY
CEG
VST
CLS
VRT
CAMT
EME
NVDA
TVK.TO
AMD
VRT
DELL
FNGU
AVGO
IESC
CAMT
FIX
WING
MSTR
LLY
NVO
META
1 / 176

Recent discussions